BR112016026787A2 - - Google Patents

Info

Publication number
BR112016026787A2
BR112016026787A2 BR112016026787A BR112016026787A BR112016026787A2 BR 112016026787 A2 BR112016026787 A2 BR 112016026787A2 BR 112016026787 A BR112016026787 A BR 112016026787A BR 112016026787 A BR112016026787 A BR 112016026787A BR 112016026787 A2 BR112016026787 A2 BR 112016026787A2
Authority
BR
Brazil
Application number
BR112016026787A
Other versions
BR112016026787A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016026787A2 publication Critical patent/BR112016026787A2/pt
Publication of BR112016026787A8 publication Critical patent/BR112016026787A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112016026787A 2014-05-16 2015-05-13 Derivados de quinzaolina-4(3h)-ona antibacterianos BR112016026787A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14168718 2014-05-16
PCT/EP2015/060653 WO2015173329A1 (en) 2014-05-16 2015-05-13 Antibacterial quinazoline-4(3h)-one derivatives

Publications (2)

Publication Number Publication Date
BR112016026787A2 true BR112016026787A2 (pt) 2017-08-15
BR112016026787A8 BR112016026787A8 (pt) 2017-12-26

Family

ID=50731968

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016026787A BR112016026787A8 (pt) 2014-05-16 2015-05-13 Derivados de quinzaolina-4(3h)-ona antibacterianos

Country Status (19)

Country Link
US (1) US9796686B2 (pt)
EP (1) EP3143007B1 (pt)
JP (1) JP2017515906A (pt)
KR (1) KR20170005105A (pt)
CN (1) CN106458931A (pt)
AR (1) AR100428A1 (pt)
AU (1) AU2015261540A1 (pt)
BR (1) BR112016026787A8 (pt)
CA (1) CA2948077A1 (pt)
CL (1) CL2016002918A1 (pt)
EA (1) EA201692305A1 (pt)
ES (1) ES2687040T3 (pt)
IL (1) IL248922A0 (pt)
MX (1) MX2016014989A (pt)
PH (1) PH12016502253A1 (pt)
SG (1) SG11201609286VA (pt)
TW (1) TW201625559A (pt)
WO (1) WO2015173329A1 (pt)
ZA (1) ZA201608680B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
MX360983B (es) 2013-12-19 2018-11-22 Idorsia Pharmaceuticals Ltd Derivados antibacterianos de 1h-indazol y 1h-indol.
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
AR105646A1 (es) * 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
EP3341378A1 (en) * 2015-08-28 2018-07-04 Idorsia Pharmaceuticals Ltd Antibacterial annulated pyrrolidin-2-one derivatives
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
KR20180088456A (ko) * 2015-12-08 2018-08-03 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 항박테리아 화합물로서의 치환된 벤자지논
IL295050A (en) 2016-04-01 2022-09-01 Recurium Ip Holdings Llc Estrogen receptor modulators
US10160724B2 (en) * 2016-09-28 2018-12-25 Dong-A St Co., Ltd. Tetrahydropyridine derivatives and their use as antibacterial agents
JP2022543832A (ja) 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0970046T3 (da) 1997-02-27 2004-04-13 Wyeth Corp N-Hydroxy-2-(alkyl-, aryl- eller heteroarylsulfanyl, -sulfinyl eller -sulfonyl)-3-substituerede alkyl- eller heteroaryl-amider som matrixmetalloproteinaseinhibitorer
EP3000810B1 (en) 2002-03-13 2017-07-19 Array Biopharma, Inc. N3 alkylated benzimidazole derivative as mek inhibitor
CN107021895A (zh) * 2007-06-12 2017-08-08 尔察祯有限公司 抗菌剂
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−n−オキシドを有する新規ヒドロキサム酸誘導体
JP2012504556A (ja) 2008-10-03 2012-02-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
DE102008044132A1 (de) 2008-11-27 2010-06-02 BSH Bosch und Siemens Hausgeräte GmbH Kältegerät mit zweiseitig anschlagbarer Tür
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
WO2011045703A2 (en) 2009-10-13 2011-04-21 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
SI2512474T1 (sl) * 2009-12-16 2014-12-31 Pfizer Inc. N-vezani derivati hidroksamske kisline, uporabni kot protibakterijska sredstva
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EA201390626A1 (ru) 2010-11-10 2013-12-30 Эйкеоджен, Инк. Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций
WO2012093809A2 (en) 2011-01-03 2012-07-12 Hanmi Pharm Co., Ltd. New bicyclic compound for modulating g protein-coupled receptors
MX341977B (es) * 2011-03-07 2016-09-07 Pfizer Derivados de fluoro-piridinona utiles como agentes antibacterianos.
CA2830866A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
US8748466B2 (en) 2011-04-08 2014-06-10 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
AU2012267622B2 (en) 2011-06-08 2017-06-22 Sunovion Pharmaceuticals, Inc. Metabotropic glutamate receptor 5 modulators and methods of use thereof
WO2013170030A1 (en) 2012-05-09 2013-11-14 Achaogen, Inc. Antibacterial agents
WO2013170165A1 (en) * 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
US10647664B2 (en) 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
MX360983B (es) 2013-12-19 2018-11-22 Idorsia Pharmaceuticals Ltd Derivados antibacterianos de 1h-indazol y 1h-indol.
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona

Also Published As

Publication number Publication date
JP2017515906A (ja) 2017-06-15
PH12016502253A1 (en) 2017-01-16
SG11201609286VA (en) 2016-12-29
BR112016026787A8 (pt) 2017-12-26
EP3143007A1 (en) 2017-03-22
MX2016014989A (es) 2017-03-31
US20170081292A1 (en) 2017-03-23
IL248922A0 (en) 2017-01-31
EP3143007B1 (en) 2018-07-11
ZA201608680B (en) 2018-11-28
CN106458931A (zh) 2017-02-22
ES2687040T3 (es) 2018-10-23
AU2015261540A1 (en) 2017-01-12
TW201625559A (zh) 2016-07-16
CA2948077A1 (en) 2015-11-19
EA201692305A1 (ru) 2017-05-31
CL2016002918A1 (es) 2017-04-07
KR20170005105A (ko) 2017-01-11
WO2015173329A1 (en) 2015-11-19
AR100428A1 (es) 2016-10-05
US9796686B2 (en) 2017-10-24

Similar Documents

Publication Publication Date Title
BR112016020776A2 (pt)
BR112016027525A2 (pt)
BR112016021201A2 (pt)
BR112016027506A2 (pt)
BR112016018868A2 (pt)
BR112016020142A2 (pt)
BR112016026300A2 (pt)
BR112016026807A2 (pt)
BR112016021197A2 (pt)
BR112016023487A2 (pt)
BR112016020096A2 (pt)
BR112016020291A2 (pt)
BR112016019099A2 (pt)
JP1528637S (pt)
RU2016129508A3 (pt)
BR112016019970A2 (pt)
BR112016022105A2 (pt)
BR112016027088A2 (pt)
BR112016022869A2 (pt)
BR112016018965A2 (pt)
BR112016018830A2 (pt)
BR112016020091A2 (pt)
BR112016019638A2 (pt)
BR112016026370A2 (pt)
BR112016019543A2 (pt)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]